文献速递免疫规划

SARS-CoV-2黏膜疫苗可预防临床疾病且效力存在性别偏倚

SARS-CoV-2 mucosal vaccine protects against clinical disease with sex bias in efficacy.
PubMed 文献 · Vaccine · 2023-12-08

该研究在仓鼠中评估鼻内黏膜亚单位疫苗加强免疫对SARS-CoV-2 beta变异株的保护效果。结果显示,以beta变异株S1加强可预防体重下降并降低病毒载量,保护效力与血清抗体滴度相关;雌性免疫应答及抗病毒载量保护均强于雄性;用武汉株S1初免对beta变异株的体液免疫和保护较弱,提示抗原匹配的重要性。

要点

  • 鼻内黏膜亚单位疫苗加强可预防体重下降并降低病毒载量。
  • 保护效力与血清抗体滴度相关,雌性免疫应答和抗病毒载量保护强于雄性。
  • 武汉株S1初免对beta变异株的体液免疫和保护较弱,提示抗原匹配重要。

核心结论

  • 鼻内黏膜亚单位疫苗加强可预防临床疾病并降低病毒载量,效力存在性别偏倚,且抗原匹配影响保护效果。

研究设计与样本

  • 在仓鼠中开展鼻内亚单位黏膜疫苗加强免疫研究,评估对beta变异株S1的保护效果。

主要发现

  • 鼻内亚单位黏膜疫苗加强可预防体重下降并降低病毒载量。
  • 保护效力与血清抗体滴度相关。
  • 雌性免疫应答和抗病毒载量保护均强于雄性。
  • 用武汉株S1初免对beta变异株的体液免疫应答较低,对beta变异株攻击的保护较弱。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intranasal mucosal vaccines can more effectively induce mucosal immune responses against SARS-CoV-2. Here, we show in hamsters that an intranasal subunit mucosal vaccine boost with the beta variant S1 can prevent weight loss, in addition to reducing viral load, which cannot be studied in macaques that don't develop COVID-like disease. Protective efficacy against both viral load and weight loss correlated with serum antibody titers. A sex bias was detected in that immune responses and protection against viral load were greater in females than males. We also found that priming with S1 from the Wuhan strain elicited lower humoral immune responses against beta variant and led to less protection against beta viral challenge, suggesting the importance of matched antigens. The greater efficacy of mucosal vaccines in the upper respiratory tract and the need to consider sex differences in vaccine protection are important in the development of future improved COVID-19 vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sui Y, Andersen H, Li J, et al. SARS-CoV-2 mucosal vaccine protects against clinical disease with sex bias in efficacy. Vaccine. 2023. PMID: 38071106. doi:10.1016/j.vaccine.2023.11.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。